PDS Biotechnology Corp

PDSBSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1472091

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Research and Development Expense	$27.8M	$29.4M	$11.3M	$7.9M	$6.1M
Operating Expenses	$43.0M	$41.7M	$21.4M	$14.9M	$21.0M
Operating Income (Loss)	-$43.0M	-$41.7M	-$21.4M	-$14.9M	-$21.0M
Interest Expense	—	$1.3M	$0.00	—	$33.6K
Nonoperating Income (Expense)	—	—	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$44.3M	-$42.1M	-$21.4M	-$14.8M	—
Income Tax Expense (Benefit)	-$1.4M	-$1.2M	-$4.5M	$0.00	-$381.5K
Net Income (Loss) Attributable to Parent	-$9.7M	-$8.5M	-$3.0M	-$14.8M	-$7.0M
Earnings Per Share, Basic	-$1.39	-$1.43	-$0.66	-$0.89	—
Earnings Per Share, Diluted	-$1.39	-$1.43	-$0.66	-$0.89	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$59.4M	$77.0M	$67.2M	$30.9M	$14.5M
Assets, Current	$59.1M	$76.5M	$66.8M	$30.3M	$14.5M
Cash and Cash Equivalents, at Carrying Value	$56.6M	$73.8M	$65.2M	$28.8M	$12.2M
Liabilities	$33.3M	$33.0M	$4.0M	$3.8M	$2.8M
Liabilities, Current	$13.6M	$9.8M	$3.8M	$3.3M	$2.8M
Long-term Debt	—	—	—	—	—
Accounts Payable, Current	$7.0M	$1.2M	$1.3M	$1.4M	$1.2M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$33.6M	-$25.7M	-$12.5M	-$13.1M	-$18.1M
Net Cash Provided by (Used in) Investing Activities	$0.00	—	—	—	$29.4M
Net Cash Provided by (Used in) Financing Activities	$16.4M	$34.3M	$48.9M	$29.8M	$750.0K
Payments to Acquire Property, Plant, and Equipment	$0.00	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)